Company intelligence / Profile preview
Promius Pharma
Princeton, New Jersey, USA
- Ownership
- Private
- Employees
- ~51
- Development stage
- Other
01
Overview
Promius Pharma marketed innovative small molecule dermatology and neurology products (notably in migraine), but US rights to key dermatology assets were sold to Encore Dermatology in 2019; remaining pipeline assets are discontinued, withdrawn, or early clinical.
- Therapeutic areas
- NeurologyInfectious DiseasesCardiovascular
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →03
Partnerships
Encore Dermatology (2019 US rights sales for SERNIVO, PROMISEB, and TRIANEX)
Beyond the preview
Go deeper on Promius Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Promius Pharma.